PRPH (ProPhase Labs) Ending Cash Position: $0.03 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ProPhase Labs Ending Cash Position?

ProPhase Labs PRPH -10.01% Ending Cash Position is $0.03 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

ProPhase Labs's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.03 Mil.

ProPhase Labs's quarterly Ending Cash Position increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.09 Mil) but then declined from Dec. 2025 ($0.09 Mil) to Mar. 2026 ($0.03 Mil).

ProPhase Labs's annual Ending Cash Position declined from Dec. 2023 ($1.61 Mil) to Dec. 2024 ($0.68 Mil) and declined from Dec. 2024 ($0.68 Mil) to Dec. 2025 ($0.09 Mil).

ProPhase Labs Ending Cash Position Related Terms

ProPhase Labs Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ProPhase Labs's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProPhase Labs Ending Cash Position Chart

ProPhase Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.66 9.11 1.61 0.68 0.09

ProPhase Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.17 0.00 0.09 0.03

ProPhase Labs Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ProPhase Labs's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.678+-0.588
=0.09

ProPhase Labs's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.09+-0.059
=0.03

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.03 Mil mean?
ProPhase Labs (PRPH) has a Ending Cash Position of $0.03 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ProPhase Labs and its competitors.
Is ProPhase Labs' Ending Cash Position too high?
ProPhase Labs' current Ending Cash Position is $0.03 Mil.
How does ProPhase Labs' Ending Cash Position compare to IDTA and IVRO?
ProPhase Labs' Ending Cash Position of $0.03 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ProPhase Labs and its competitors. ProPhase Labs's current Ending Cash Position is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.92, compared to a current price of $0.06 — trading 93.5% below its estimated fair value. The current Ending Cash Position is $0.03 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Ending Cash Position is $0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProPhase Labs Business Description

Address 626 RXR Plaza, 6th Floor, Uniondale, NY, USA, 11556
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.